Imexon - CAS 59643-91-3
Catalog number:
59643-91-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Description:
Imexon is a cyanoaziridine derivatives with potential anticancer activity.  Imexon belongs to a novel class of promising anticancer agents that induce tumor apoptosis through oxidative stress. Although its mechanism of action is not clearly known, imexon may induce apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8. Other cytotoxic mechanisms of action of this agent may involve thiol depletion, generation of reactive oxygen species (ROS), and decreases in the mitochondrial membrane potential.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
AIDS000351; AIDS-000351; BM06002; Imexon;
MSDS:
Inquire
Current Developer:
Direct Therapeutics, Inc.
1.Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.
Dorr RT1, Wisner L, Samulitis BK, Landowski TH, Remers WA. Cancer Chemother Pharmacol. 2012 Apr;69(4):1039-49. doi: 10.1007/s00280-011-1784-8. Epub 2011 Dec 21.
PURPOSE: Preclinical studies evaluated the anti-tumor activity and mechanism of action of AMP423, a naphthyl derivative of 2-cyanoaziridine-1-carboxamide with structural similarity to the pro-oxidant anti-tumor agent imexon.
2.Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
Samulitis BK1, Dorr RT, Chow HH. Anticancer Res. 2011 Sep;31(9):2781-5.
AIM: We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.
3.Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium.
Guntle GP1, Jagadish B, Mash EA, Powis G, Dorr RT, Raghunand N. Transl Oncol. 2012 Jun;5(3):190-9. Epub 2012 Jun 1.
Gd-LC6-SH is a thiol-bearing DOTA complex of gadolinium designed to bind plasma albumin at the conserved Cys(34) site. The binding of Gd-LC6-SH shows sensitivity to the presence of competing thiols. We hypothesized that Gd-LC6-SH could provide magnetic resonance imaging (MRI) enhancement that is sensitive to tumor redox state and that the prolonged retention of albumin-bound Gd-LC6-SH in vivo can be exploited to identify a saturating dose above which the shortening of MRI longitudinal relaxation time (T(1)) of tissue is insensitive to the injected gadolinium dose. In the Mia-PaCa-2 pancreatic tumor xenograft model in SCID mice, both the small-molecule Gd-DTPA-BMA and the macromolecule Galbumin MRI contrast agents produced dose-dependent decreases in tumor T(1). By contrast, the decreases in tumor T(1) provided by Gd-LC6-SH at 0.05 and 0.1 mmol/kg were not significantly different at longer times after injection. SCID mice bearing Mia-PaCa-2 or NCI-N87 tumor xenografts were treated with either the glutathione synthesis inhibitor buthionine sulfoximine or the thiol-oxidizing anticancer drug Imexon, respectively.
4.Identification of drugs that restore primary cilium expression in cancer cells.
Khan NA1, Willemarck N1, Talebi A1, Marchand A2, Binda MM1, Dehairs J1, Rueda-Rincon N1, Daniels VW1, Bagadi M1, Raj DB3, Vanderhoydonc F1, Munck S4,5, Chaltin P2,6, Swinnen JV1. Oncotarget. 2016 Mar 1;7(9):9975-92. doi: 10.18632/oncotarget.7198.
The development of cancer is often accompanied by a loss of the primary cilium, a microtubule-based cellular protrusion that functions as a cellular antenna and that puts a break on cell proliferation. Hence, restoration of the primary cilium in cancer cells may represent a novel promising approach to attenuate tumor growth. Using a high content analysis-based approach we screened a library of clinically evaluated compounds and marketed drugs for their ability to restore primary cilium expression in pancreatic ductal cancer cells. A diverse set of 118 compounds stimulating cilium expression was identified. These included glucocorticoids, fibrates and other nuclear receptor modulators, neurotransmitter regulators, ion channel modulators, tyrosine kinase inhibitors, DNA gyrase/topoisomerase inhibitors, antibacterial compounds, protein inhibitors, microtubule modulators, and COX inhibitors. Certain compounds also dramatically affected the length of the cilium.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 59643-91-3 Imexon

Quick Inquiry

Verification code

Featured Items